The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's drug for patients with a rare and ...

Nuvation Bio is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment ...

Read the latest analysis on Nuvation Bio stock. Solid financials, positive analyst sentiment, and insider buying support ...

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Nuvation Bio Inc.

US FDA approves Nuvation Bio’s taletrectinib for treatment of advanced ROS1-positive non-small cell lung cancer: New York Saturday, June 14, 2025, 14:00 Hrs [IST] Nuvation Bio I ...

FDA approves Ibtrozi for ROS1+ non-small cell lung cancer based on data from over 300 patients in two pivotal trials showing ...

The US Food and Drug Administration (FDA) has approved Nuvation Bio’s Ibtrozi (taletrectinib) to treat adults with a rare and ...

Nuvation Bio Inc. (NYSE:NUVB) has recently achieved a significant milestone with the FDA approval of its flagship drug IBTROZI (taletrectinib) for the treatment of ROS1-positive non-small cell ...

The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's therapy for patients with a type of ...